PepGen (PEPG) Financials

PepGen’s latest quarter shows a company with a very strong cash position, no revenue yet, and continued heavy spending on research and development. The business remains in development mode, so investors should focus less on sales growth and more on cash runway, expense trends, and whether the balance sheet can support clinical progress.

• Strong liquidity remains intact: PepGen ended Q1 2026 with $42.2 million in cash and equivalents plus $90.2 million in short-term investments, or about $132.3 million in liquid assets.
• Balance sheet still carries substantial equity: Total equity was $134.0 million at the end of Q1 2026, which helps cushion the company while it is pre-revenue.
• Interest income is helping offset losses: Q1 2026 interest and investment income of $1.25 million provided a meaningful boost to pre-tax results.
• Operating cash burn improved slightly year over year: Net cash used in operating activities was $18.4 million in Q1 2026 versus $22.9 million in Q1 2025.
• Funding flexibility remains available: PepGen raised $1.5 million from common equity issuance in Q1 2026, showing continued access to capital markets.
• Revenue is still absent: The company reported $0 revenue in Q1 2026 and across the periods shown, so the investment case still depends on pipeline progress rather than commercial sales.
• R&D remains the main expense driver: Research and development expense was $13.0 million in Q1 2026, the largest line item on the income statement, which is typical for a biotech company in development.
• Non-cash charges matter, but don’t solve the cash burn: Depreciation, amortization, and other non-cash adjustments helped soften reported losses, yet operating cash flow remained negative.
• Losses remain large: PepGen posted a Q1 2026 net loss of $17.8 million, only slightly better than the $18.3 million loss in Q4 2025.
• Cash and investments declined sharply from late 2025: Liquid assets fell from about $163.0 million in Q3 2025 to $132.3 million in Q1 2026, reflecting ongoing burn.

Looking at the broader trend over the last four years, PepGen has consistently operated at a loss while spending heavily on R&D. Quarterly net losses have generally ranged from roughly $18 million to $30 million, and operating cash flow has been negative every period shown. That pattern is normal for a clinical-stage biotech, but it means the stock’s long-term value depends heavily on trial data and financing execution.

One encouraging trend is that PepGen’s cash balance improved dramatically in 2025 after equity financing, then settled at a still-healthy level in early 2026. However, the company is now drawing down that cash again. If clinical development takes longer than expected, investors should expect additional dilution or financing needs down the road.

Bottom line: PepGen appears financially stable in the near term, but it is still a cash-burning, pre-revenue biotech. The stock’s outlook will likely hinge on pipeline milestones, because the financial statements alone do not yet show a self-sustaining business.